Contrast media are chemical compounds used to increase the visibility of structures during x-rays. Iodine-based compounds are most commonly used intravascularly. Over time, contrast media have evolved from high-osmolar ionic compounds to lower-osmolar non-ionic versions to reduce adverse reactions. Potential adverse reactions include mild allergic-like symptoms but can occasionally be life-threatening. Proper patient screening and premedication can help reduce risks. Special populations like children, pregnant women, and those with impaired kidney function require additional precautions with contrast media use.
Complications of anesthesia
This topic aim to provide information on some common clinical condition that occur to the patients after anesthetized required procedure
SEMINAR PRESENTATION ON CONTRAST INDUCED NEPHROPATHY BY PHARM D STUDENT
IT INCLUDES COMPLETE OVERVIEW OF THE TOPIC CIN.
POST CONTRAST ACUTE KIDNEY INJURY( PC-AKI) WITH TREATMENT AND MANAGEMENT.
Founded in 1992, Beilu is a high-tech innovation company with core competence in diagnostic imaging field in China. It has around 650 employees with 0.82 Bn¥ revenue in 2019. We have the most complete Contrast media categories and are the leading manufacture in Contrast media field in China. It is one of the 1st batch of listed enterprises in GEM in China. Beilu s main products are Contrast media, psychoneurosis traditional Chinese medicine and endocrinology drugs that to benefit people and improve their quality of life. Contrast media are widely used to improve pictures of the inside of the body produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging etc.. Psychoneurosis traditional Chinese medicine are the original products with Chinese patent to contribution to improve the physical and mental status. In 2020, Beilu Pharma completed the acquisition of Hichi Pharm to realize the layout of industrial chain integration.
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...University of Maribor
Slides from:
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Track: Artificial Intelligence
https://www.etran.rs/2024/en/home-english/
Complications of anesthesia
This topic aim to provide information on some common clinical condition that occur to the patients after anesthetized required procedure
SEMINAR PRESENTATION ON CONTRAST INDUCED NEPHROPATHY BY PHARM D STUDENT
IT INCLUDES COMPLETE OVERVIEW OF THE TOPIC CIN.
POST CONTRAST ACUTE KIDNEY INJURY( PC-AKI) WITH TREATMENT AND MANAGEMENT.
Founded in 1992, Beilu is a high-tech innovation company with core competence in diagnostic imaging field in China. It has around 650 employees with 0.82 Bn¥ revenue in 2019. We have the most complete Contrast media categories and are the leading manufacture in Contrast media field in China. It is one of the 1st batch of listed enterprises in GEM in China. Beilu s main products are Contrast media, psychoneurosis traditional Chinese medicine and endocrinology drugs that to benefit people and improve their quality of life. Contrast media are widely used to improve pictures of the inside of the body produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging etc.. Psychoneurosis traditional Chinese medicine are the original products with Chinese patent to contribution to improve the physical and mental status. In 2020, Beilu Pharma completed the acquisition of Hichi Pharm to realize the layout of industrial chain integration.
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...University of Maribor
Slides from:
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Track: Artificial Intelligence
https://www.etran.rs/2024/en/home-english/
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...Wasswaderrick3
In this book, we use conservation of energy techniques on a fluid element to derive the Modified Bernoulli equation of flow with viscous or friction effects. We derive the general equation of flow/ velocity and then from this we derive the Pouiselle flow equation, the transition flow equation and the turbulent flow equation. In the situations where there are no viscous effects , the equation reduces to the Bernoulli equation. From experimental results, we are able to include other terms in the Bernoulli equation. We also look at cases where pressure gradients exist. We use the Modified Bernoulli equation to derive equations of flow rate for pipes of different cross sectional areas connected together. We also extend our techniques of energy conservation to a sphere falling in a viscous medium under the effect of gravity. We demonstrate Stokes equation of terminal velocity and turbulent flow equation. We look at a way of calculating the time taken for a body to fall in a viscous medium. We also look at the general equation of terminal velocity.
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
Toxic effects of heavy metals : Lead and Arsenicsanjana502982
Heavy metals are naturally occuring metallic chemical elements that have relatively high density, and are toxic at even low concentrations. All toxic metals are termed as heavy metals irrespective of their atomic mass and density, eg. arsenic, lead, mercury, cadmium, thallium, chromium, etc.
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...Travis Hills MN
Travis Hills of Minnesota developed a method to convert waste into high-value dry fertilizer, significantly enriching soil quality. By providing farmers with a valuable resource derived from waste, Travis Hills helps enhance farm profitability while promoting environmental stewardship. Travis Hills' sustainable practices lead to cost savings and increased revenue for farmers by improving resource efficiency and reducing waste.
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptxRASHMI M G
Abnormal or anomalous secondary growth in plants. It defines secondary growth as an increase in plant girth due to vascular cambium or cork cambium. Anomalous secondary growth does not follow the normal pattern of a single vascular cambium producing xylem internally and phloem externally.
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...University of Maribor
Slides from talk:
Aleš Zamuda: Remote Sensing and Computational, Evolutionary, Supercomputing, and Intelligent Systems.
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Inter-Society Networking Panel GRSS/MTT-S/CIS Panel Session: Promoting Connection and Cooperation
https://www.etran.rs/2024/en/home-english/
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skills
BREEDING METHODS FOR DISEASE RESISTANCE.pptxRASHMI M G
Plant breeding for disease resistance is a strategy to reduce crop losses caused by disease. Plants have an innate immune system that allows them to recognize pathogens and provide resistance. However, breeding for long-lasting resistance often involves combining multiple resistance genes
2. Introduction
Contrast media - Group of chemical compounds that increase or
decrease the x ray attenuation and therefore increase the
contrast of the structures that contains them
Group - Negative contrast (Air)
Positive contrast (Iodine compounds, Barium)
Iodine is the only element that has proved satisfactory for general
use as intravascular radiological contrast media.
3. History and development
1923
◦ First report of opacification of urinary tract by renal excretion of injected 10% sodium iodide used for
treatment of syphilis
◦ Selectan neutral, - excreted in urine but image quality was poor
1929
◦ Some modification to molecule was done and first intravenous urogram was performed with compound
uroselectan (monoiodinated compound)
◦ Later, Di-iodinated compound (Uroselectan B & Diodone) were developed
1952
◦ First Tri-iodinated sodium acetrizoate (Urokon) was introduced
◦ 6 carbon ring structure, tri-iodobenzoic acid - precursor of all modern water soluble contrast media
4. 1955
◦ Much safer derivative – Diatrizoate (Urograffin, Hypaque) introduced
1962
◦ Iothalamate (Conray)
All conventional contrast media are ionic and had high osmolality (4-7 times of plasma)
Most of the contrast related adverse effects were related to high osmolality of the contrast
Further developments were directed towards reducing the osmality of contrast without
changing the iodine concentration, or even increasing iodine concentration
5. Newer development of contrast proceeded
1. Combine two tri-iodinated benzene rings to produce anion with 6 iodine atoms (Dimeric Diacidic) –
iocarmate
2. Replacement of one carboxylic acid group in dimer with non ionizing radical (Dimeric Monoacidic) -
Ioxaglate
3. Produce compound that doesnot ionize in solution (Monomeric, non acidic) – iopamidol, iohexol,
iopramide, Iopental, Iosversol, Iopramide.
4. Non ionizing Dimeric compound – Iotrolan, Iodixanol
6. Osmolality
Osmolality is the total number of molecule or particle
present in one kilogram of solution
Osmolality of:
◦ Blood/Plasma – 300
◦ Low osmolar contrast media – 400-700
◦ High osmolar contrast media – 1400 – 1800
7. Advantage of LOCM over HOCM
Advantages : Less tissue toxicity
Less adverse effects
Disadvantage: High cost as compared to HOCM
Indication:
◦ In those at high risk of hyperosmolar effects of HOCM eg. Children, Elderly,
Renal or Cardiac failure patients, Poorly hydrated, Diabetics, Sickle cell
anaemia, Multiple myeloma etc.
◦ Those with previous reaction with contrast
◦ Procedures requiring high dose of contrast
12. Patient Preparation
3 H’s
History
◦ Past history of contrast reactions
◦ Asthma, Heart disease, Renal insufficiency, Thyroid disorder,
Diabetes, Myeloma, Sickle cell disease, Paraproteinaemias
◦ Drug history – Metformin, Aminoglycosides
Hydration
Have equipment and expertise ready
13. Adverse events after IV iodinated contrast media
administration
Frequency of adverse events related to intravascular administration
of iodinated contrast media is low and has decreased considerably
with change in usage from ionic HOCM to non ionic LOCM
Majority of adverse side effects are mild and non life threatening
Usually require only observation, reassurance and supportive
measures
Life threatening adverse effects however can occur and usually
noted within 20 minutes of contrast administration
14. Acute adverse events
Allergic like reactions
◦ Identical to anaphylactic reaction to drug or other allergen
◦ Since antigen antibody response cannot be identified they are classified as
“anaphylactoid”, “allergic like”, or “idiosyncratic” reactions
◦ Pathogenesis is unclear, ICM causes release of histamine from basophils and
mast cells
◦ Other possible pathways – activation, deactivation or inhibition of variety of
vasoactive substances (histamine, compliment and kinins)
15. Categories of Reaction
Mild
Signs and symptoms appear self-limited without evidence of progression (e.g., limited urticaria
with mild pruritus, transient nausea, one episode of emesis) and include:
Treatment: Requires observation to confirm resolution and/or lack of progression but usually no
treatment. Patient reassurance is usually helpful.
• Nausea, vomiting
• Altered taste
• Sweats
• Cough
• Itching
• Rash, hives
• Warmth
• Pallor
• Nasal stuffiness
• Headache
• Flushing
• Swelling: eyes, face
• Dizziness
• Chills
• Anxiety
• Shaking
16. Moderate
Signs and symptoms are more pronounced. Moderate degree of clinically evident focal or
systemic signs or symptoms, including:
Treatment: Clinical findings in moderate reactions frequently require prompt treatment. These
situations require close, careful observation for possible progression to a life-threatening event.
• Tachycardia/bradycardia
• Bronchospasm, wheezing
• Hypertension
• Laryngeal edema
• Generalized or diffuse erythema
• Mild hypotension
• Dyspnea
17. Severe
Signs and symptoms are often life-threatening, including:
Treatment: Requires prompt recognition and aggressive treatment; manifestations and
treatment frequently require hospitalization.
• Laryngeal edema (severe or rapidly
progressing)
• Convulsions
• Unresponsiveness
• Profound hypotension
• Cardiopulmonary arrest
• Clinically manifest arrhythmias
18. Treatment of adverse effects following ICM
Mild adverse effects
◦ Iv access should be maintained
◦ Observation
◦ Reassurance
◦ Oral anti histaminics
Severe reactions
◦ 100 % O2 10-15 l/min
◦ Salbutamol nebulization (5mg in 2 ml) for wheeze
◦ Hypotension – Rapid infusion of iv fluids
◦ Bradycardia – Atropine 0.6 mg, can be repeated every 5 minute till maximum of 3 mg
◦ Bronchospasm, urticarial, laryngeal odema – 500 mg of hydrocortisone, 10 mg of chlorpheniramine iv
slowly over 1-2 min,
◦ Life threatening hypotension – Adrenaline 500 µg (0.5 ml of 1:1000) im.
19. Breakthrough Reactions
•Adverse reactions in pre-medicated patients with past history of contrast reactions is called
breakthrough reaction
•Pre-medications decreases frequency of breakthrough reaction
•Breakthrough reactions are less with use of LOCM
•Severe allergy to other drugs or other allergens are at higher risk
20. Premedications
Elective Premedication
Two frequently used regimens are:
Prednisone – 50 mg , PO 13 hours, 7 hours, and 1 hour before contrast media injection
+
Diphenhydramine – 50 mg iv/im/PO, 1 hour before contrast medium .
OR
Methylprednisolone – 32 mg, PO 12 hrs and 2 hrs before contrast media injection.
An anti-histamine (as in option 1) can also be added to this regimen injection
If the patient is unable to take oral medication, 200 mg of hydrocortisone intravenously may be
substituted for oral prednisone.
21. Emergency Premedication
1. Methylprednisolone 40 mg or hydrocortisone 200 mg intravenously every 4 hours until
contrast study required plus diphenhydramine 50 mg IV 1 hour prior to contrast injection
2. Dexamethasone 7.5 mg or betamethasone 6.0 mg intravenously 4h until contrast study must
be done in patient with known allergy to methylprednisolone, aspirin, or non-steroidal anti-
inflammatory drugs, especially if asthmatic. Also diphenhydramine 50 mg IV 1 hour prior to
contrast injection.
IV steroids have not been shown to be effective when administered less than 4 to 6 hours prior
to contrast injection.
22. Organ specific adverse effects
Vascular
◦ Venous –pain at site of injection d/t perivenous injection, pain extending up arm – d/t stasis of contrast,
delayed limb pain – d/t thrombophlebitis
◦ Arterial – endothelial damage
Soft tissue – pain swelling and ulceration d/t extravasation of contrast
Cardiovascular
◦ Intracoronary injection – ventricular fibrillation, arrhythmia, heart block
◦ Increased vagal activation causing bradycardia
◦ Volume overload leading to heart failure, pulmonary odema
23. Hematological
◦ Hemolysis
◦ RBC aggregation and coagulation
◦ Platelet dysfunction, potentiation of heparin
◦ Sickle cell crisis
◦ Transient eosinophilia
Neurotoxicity
◦ Seizures in patients with epilepsy and cerebral tumors or secondary to hypotension following cardiac arrest
◦ Less with LOCM
Thyroid dysfunction
◦ Thyrotoxicosis in patient with non toxic goiter
◦ Interfere with TFT
24. Nephrotoxicity
Incidence of nephrotoxicity following ICM administration is around 5%
Majority of renal impairment are temporary
Predisposing factors :
◦ Pre existing renal impairment (present in 90%)
◦ Diabetes mellitus
◦ Dehydration
◦ Age
◦ Dose of contrast
◦ Multiple myeloma
◦ Other nephrotoxic drugs (Aminoglycosides, NSAIDs, Metformin)
25. Mechanism of renal impairment – exact pathophysiology not known
◦ Hypoperfusion of kidneys
◦ adverse cardiac effects leading to Increased vasodilation
◦ Predehydration
◦ Osmotic diuresis
◦ Glomerular injury and tubular injury
◦ Impaired perfusion
◦ Chemotoxic effect of contrast
◦ Obstructive nephropathy
◦ Precipitation of Tamm-Horsfall protein
◦ Precipitation of Bence jones protein
26. Diagnosis
◦Increase in 25 – 50% of baseline creatinine level
◦Increase in 0.5 mg/dl of creatinine
Acute kidney injury network (AKIN) criteria
◦Following findings within 48 hours of nephrotoxic event
1. Absolute serum creatinine increase of >0.3 mg/dl
2. Percentage increase in creatinine ≥ 50 % above baseline
3. Urine output reduced to ≤ 0.5 ml/kg/hour for at least 6 hrs
27. Contrast extravasation
•Incidence 0.1 – 0.9 %
•Can occur during hand or power injection
•Initial sign and symptoms – swelling or tightness, stinging or burning pain,
edematous erythematous and tenderness at site of extravasation
•Sequelae – causes local acute inflammatory response esp. to skin peaks in 24 –
48 hrs
•Usually no permanent injury
•Most common severe injury - compartment syndrome
•Others – skin ulceration, tissue necrosis
28. Treatment
◦ No clear consensus
◦ Elevation of limb
◦ Hot/cold compression
◦ Aspiration of extravasated contrast
◦ Surgical consultation for severe injuries eg. Compartment syndrome or symptoms – progressive
swelling, altered sensation, decreased capillary refill time, skin ulceration or blistering
Risk for extravasation
◦ Infants, elderly and debilitated patients who cannot communicate effectively
◦ Patients with vascular diseases – atherosclerosis, thrombosis, radiotherapy, diabetics
◦ Vascular sites – hand and wrist, foot and ankle
◦ Contrast injection through indwelling catheter placed more than 24 hrs
30. Contrast in children
•Neonates and small children are more susceptible to fluid
shifts hence have lower tolerance for osmotic load
•Small caliber iv cannula cause difficulty in injection viscous
contrast media
•Usual dosing – 2ml/kg, injected at slower rate – 1.5ml/s
31. Metformin and ICM
•Iodianted contrast is not an independent risk factor for patient taking Metformin, but is of
concern in presence of underlying conditions of delayed renal excretion of metformin
•No reports of lactic acidosis following ICM in properly selected patients
32. ACR committee recommendations
◦ Category I – normal renal function and no known comorbidities
◦ No need to discontinue metformin
◦ No need check creatinine before resuming the metformin after 48 hrs of ICM administration
◦ Category II – apparently normal renal function but with multiple
comorbidities
◦ Discontinue the metformin at time of examination and withheld for 48 hrs
◦ No need to check creatinine if clinically stable and no other risk factors of renal damage (
aminoglycoside treatment, surgery, sepsis)
◦ Category III – patient with renal dysfunction
◦ Withheld metformin and cautious follow up of renal function should be performed until safe
reinstitution of metformin can be assured
33. Dialysis patients
•Can receive intravenous contrast media
•Theoretical risk of converting oliguric dialysis patient to anuric
dialysis patient, increased vascular load
•Contrast agents are not protein bound and are easily cleared by
dialysis
•Unless significant volume of ICM injected or underlying cardiac
dysfunction – no need for urgent dialysis
34. Pregnancy
•Iodinated contrast media crosses the placenta and enter fetus in
measurable quantities
•Limited studies about effects of ICM to human embryo
•Animal studies show no evidence of either mutagenic or teratogenic
effects with LOCM
•Considering the radiation risk and unknown risk of ICM, contrast
studies during pregnancy should only be done if,
◦ No other modalities available
◦ Information from the investigation affects the patient care drastically
◦ Investigation cannot be delayed till the end of pregnancy
35. Breast feeding
Limited studies show
◦ Less than 1% of administered ICM is excreted via breast milk
◦ Less than 1% of contrast medium in breast milk ingested by an
infant is absorbed
◦ 0.01 % administered ICM absorbed by infant, which is below the
safe level of 2ml/kg
◦ Only theoretical possibility of adverse effects
◦ Safe for breast feeding mothers to feed following contrast
investigation
36. Summary
•Contrast Media
•History and Development
•HOCM / LOCM – Disadvantages Vs Advantages
•Indications of contrast studies
•Adverse Reactions
•Treatment of contrast reactions
•Break through reactions – Mx
•Organ specific adverse reactions
•Special considerations
37. References
ACR Manual on Contrast Media, Version 8, 2012
Radiological Procedures, Chapman
Textbook of Diagnositic Imaging, D. Sutton